System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Clémentine Jankowski is an expert in Oncology at Centre Georges François Leclerc (France). Clémentine Jankowski has authored 47 publications, the most recent in 2025, and is an investigator in 2 clinical trials. SLR score: 194 (community average: 125). How the SLR is computed.

LeadR Profile

Clémentine Jankowski Centre Georges François Leclerc France
194 ScienceLeadR Reputation 194

Unlock

Register Login
Network Map

Oncology

Subspecialties: Plastic And Esthetic Surgery - Gynecology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2025
Source: PubMed

Centre Georges François Leclerc

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 47

Citations

Citations: 479 1st author: 10 Last author: 1 Unique author: 0

Main journals

Bull Cancer 5
Cancer Res 5
Breast Cancer Res Treat 3
Gynecol Obstet Fertil 3
J Clin Oncol 3

Best Journals

J Clin Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes.
PMID 40993786 — lymph nodes, breast neoplasms, neoplasms, positron emission tomography computed tomography, neoplasm metastasis, lymph, breast, therapeutics		Cancer Imaging20250
Comparison of post-operative complications after immediate breast reconstruction by muscle-sparing latissimus dorsi flap versus total latissimus dorsi flap.
PMID 40527719 — muscles, neoplasms, mammaplasty, breast, multivariate analysis		Bull Cancer20250
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
PMID 40329152 — breast neoplasms, nomograms, neoplasms, breast		Breast Cancer Res Treat20250
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.
PMID 39893163 — breast neoplasms, neoplasms, breast, prevalence, therapeutics, prognosis		NPJ Breast Cancer20250
Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.
PMID 39243563 — registries, research design, breast neoplasms, neoplasms, mandatory testing, breast, prevalence, therapeutics, mutation, prognosis, breast diseases		Breast20242

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 2

By status:

Recruiting 1
Unknown 1

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS